Development of analogs of thalidomide

Thalidomide
Drug class
Thalidomide, the parent drug of thalidomide analogs.
Class identifiers
ATC code	L04AX
Biological target	Immunosuppressant

The development of analogs of thalidomide was precipitated by the discovery of the anti-angiogenic and anti-inflammatory properties of the drug yielding a new way of fighting cancer as well as some inflammatory diseases after it had been banned in 1961. The problems with thalidomide included; teratogenic side effects, high incidence of other adverse reactions, poor solubility in water and poor absorption from the intestines.

In 1998 thalidomide was approved by the US Food and Drug Administration (FDA) for use in newly diagnosed multiple myeloma (MM) under strict regulations.^[1] This has led to the development of a number of analogs with fewer side effects and increased potency which include; lenalidomide, (currently marketed), pomalidomide and apremilast (currently marketed), all of which are manufactured by Celgene.

History

Thalidomide was originally released in the Federal Republic of Germany (West Germany) under the label of Contergan on October 1, 1957 by Chemie Grünenthal (now Grünenthal). The drug was primarily prescribed as a sedative or hypnotic, but it was also used as an antiemetic and sedative. The drug was banned in 1961 after its teratogenic properties were observed. The problems with thalidomide were, aside from the teratogenic side effects, both high incidence of other adverse reactions along with poor solubility in water and absorption from the intestines.^[2][3] Adverse reactions include peripheral neuropathy in large majority of patients, constipation, thromboembolism along with dermatological complications.^[4] Four years after thalidomide was withdrawn from the market for its ability to induce severe birth defects, its anti-inflammatory properties were discovered when patients suffering from erythema nodosum leprosum (ENL) used thalidomide as a sedative and it reduced both the clinical signs and symptoms of the disease. Thalidomide was discovered to inhibit tumour necrosis factor-alpha (TNF-α) in 1991. TNF-α is a cytokine produced by macrophages of the immune system, and also a mediator of inflammatory response. Thus the drug is effective against some inflammatory diseases such as ENL. In 1994 Thalidomide was found to have anti-angiogenic activity^[5] and anti-tumor activity^[6] which propelled the initiation of clinical trials for cancer including Multiple Myeloma. The discovery of the anti-inflammatory, anti-angiogenic and anti-tumor activities of thalidomide increased the interest of further research and synthesis of safer analogs.^[7][8]

Lenalidomide is the first analog of thalidomide which is marketed. It is considerably more potent than its parent drug with only two differences at a molecular level, with an added amino group at position 4 of the phthaloyl ring and removal of a carbonyl group from the phthaloyl ring.^[9] Development of lenalidomide began in the late 1990s and clinical trials of lenalidomide began in 2000. In October 2001 lenalidomide was granted orphan status for the treatment of MM. In mid-2002 it entered phase II and by early 2003 phase III. In February 2003 FDA granted fast-track status to lenalidomide for the treatment of relapsed or refractory MM.^[7] In 2006 it was approved for the treatment of MM along with dexamethasone and in 2007 by European Medicines Agency (EMA). In 2008, phase II trial observed efficacy in treating Non-Hodgkin's lymphoma.^[10] Pomalidomide (3-aminothalidomide) was the second thalidomide analog to enter the clinic being more potent than both of its predecessors.^[11] First reported in 2001, pomalidomide was noted to directly inhibit myeloma cell proliferation and thus inhibiting MM both on the tumor and vascular compartments.^[12] This dual activity of Pomalidomide makes it more efficacious than thalidomide in vitro and in vivo.^[13] This effect is not related to TNF alpha inhibition since potent TNF alpha inhibitors such as Rolipram and Pentoxifylline did not inhibit myeloma cell growth nor angiogenesis.^[8] Up regulation of Interferon gamma, IL-2 and IL-10 have been reported for Pomalidomide and may contribute to its anti-angiogenic and anti-myeloma activities.

Figure 1: Chronological view of the history of thalidomide and its analogs

Pharmacokinetics

Thalidomide

Thalidomide
Tmax [drug]	4 – 6 hours in subjects with MM.[14]
Protein binding	55 – 65% [15]
Metabolites	Hydrolized metabolites[15]
Half-life [t1/2]	5,5 – 7,6 hours[15]

Lenalidomide

Lenalidomide
Tmax [drug]	0,6 – 1,5 hours in healthy subjects [16] 0,5 – 4 hours in subjects with MM [17]
Protein binding	~30% [16]
Metabolites	Has not yet been studied [16]
Half-life [t1/2]	3 hours in healthy subjects [16] 3,1 – 4,2 hours in subjects with MM [17]

Pomalidomide

Pomalidomide
Tmax [drug]	0,5 – 8 hours [18]
Protein binding	Unknown
Metabolites	Unknown
Half-life [t1/2]	6,2 – 7,9 hours[18]

Apremilast

Apremilast
Tmax [drug]	1,5 – 2 hours in healthy subjects.[19] Median 2 hours in patients with severe-plaque type psorasis.[20]
Protein binding	~90% [21]
Metabolites	O-desmethyl apremilast glucuronide and demethylated apremilast along with hydrolyzed products.[19]
Half-life [t1/2]	8,2 hours[20]

Mechanism of action

Thalidomide and its analogs, lenalidomide and pomalidomide, are believed to act in a similar fashion even though their exact mechanism of action is not yet fully understood. It is believed that they work through different mechanisms in various diseases. The net effect is probably due to different mechanisms combined. Apremilast is, however, believed to work through a different mechanism and therefore will be discussed separately. Mechanism of action will be explained in light of today's knowledge, mainly in MM (Figure 2).

Thalidomide, lenalidomide and pomalidomide

Figure 2: The mechanism of TLP in multiple myeloma. TLP refers to thalidomide, lenalidomide and pomalidomide.

Altering cytokine production

Thalidomide and its immune-modulating analogs alter the production of the inflammatory cytokines TNF-α, IL-1, IL-6, IL-12 and anti-inflammatory cytokine IL-10.^[22] The analogs are believed to inhibit the production of TNF-α, where the analogs are up to 50.000 times more potent in vitro than the parent drug thalidomide.^[23] The mechanism is believed to be through enhanced degradation of TNF-α mRNA, resulting in diminished amounts of this pro-inflammatory cytokine secreted.^[24] This explains the effect of thalidomide when given to ENL patients, as they commonly have high levels of TNF-α in their blood and in dermatological lesions.^[7] In contrast, in vitro assay demonstrated that TNF-α is actually enhanced in T-cell activation, where CD4+ and CD8+ T lymphocytes were stimulated by anti-CD3^[7][23] which was later confirmed in an early phase trials involving solid tumors and inflammatory dermatologic diseases.^[24] IL-12 is another cytokine both suppressed and enhanced by thalidomide and its analogs. When monocytes are stimulated by lipopolysaccharides, IL-12 production is suppressed but during T-cell stimulation the production is enhanced.^[23]

Lenalidomide is believed to be about 1000 times more potent in vitro than thalidomide in anti-inflammatory properties and pomalidomide about 10 times more potent than lenalidomide. It is worth noticing however that, when comparing lenalidomide and pomalidomide, clinical relevance of higher in vitro potency is unclear since maximum tolerated dose of pomalidomide is 2 mg daily compared to 25 mg for lenalidomide, leading to 10-100 times lower plasma drug concentration of pomalidomide.^[25]

T-cell activation

Thalidomide and its analogs help with the co-stimulation of T-cells through the B7-CD28 complex by phosphorylating tyrosine on the CD28 receptor.^[7] In vitro data suggests this co-stimulation leads to increased Th1 type cytokine release of IFN-γ and IL-2 that further stimulates clonal T cell proliferation and natural killer cell proliferation and activity. This enhances natural and antibody dependent cellular cytotoxicity.^[26] Lenalidomide and pomalidomide are about 100-1000 times more potent in stimulating T-cell clonal proliferation than thalidomide. In addition, in vitro data suggests pomalidomide reverts Th2 cells into Th1 by enhancing transcription factor T-bet.^[22]

Anti-angiogenesis

Angiogenesis or the growth of new blood vessels has been reported to correspond with MM progression where vascular endothelial growth factor (VEGF) and its receptor, bFGF^[7] and IL-6^[23] appear to be required for endothelial cell migration during angiogenesis. Thalidomide and its analogs are believed to suppress angiogenesis through modulation of the above-mentioned factors where potency in anti-angiogenic activity for lenalidomide and pomalidomide was 2-3 times higher than for thalidomide in various in vivo assays,^[27] Thalidomide has also been shown to block NF-κB activity through the blocking of IL-6, and NF-κB has been shown to be involved in angiogenesis.^[23] Inhibition of TNF-α is not the mechanism of thalidomide's inhibition of angiogenesis since numerous other TNF-α inhibitors do not inhibit angiogenesis.^[5]

Anti-tumor activity

In vivo anti-tumor activity of thalidomide is believed to be due to the potent anti-angiogenic effect and also through changes in cytokine expression. In vitro assays on apoptosis in MM cells have been shown, when treated with thalidomide and its analogs, to up-regulate the activity of caspase8. This causes cross talking of apoptotic signaling between caspase8 and caspase9 leading to indirect up-regulation of caspase9 activity.^[22][24] Further anti-tumor activity is mediated through the inhibition of apoptosis protein-2^[27] and pro-survival effects of IGF-1, increasing sensitivity to FAS mediated cell death and enhancement of TNF-related apoptosis inducing ligand.^[24] They have also been shown to cause dose dependent G0/G1 cell cycle arrest in leukemia cell lines^[23] where the analogs showed 100 times more potency than thalidomide.^[25]

Bone marrow environment

The role of angiogenesis in the support of myleoma was first discovered by Vacca in 1994.^[28] They discovered increased bone marrow angiogenesis correlates with myeloma growth and supporting stromal cells are a significant source for angiogenic molecules in myeloma. This is believed to be a main component of the mechanism in vivo by which thalidomide inhibits multiple myeloma.

Additionally, inflammatory responses within the bone marrow are believed to foster many hematological diseases. The secretion of IL-6 by bone marrow stromal cells (BMSC) and the secretion of the adhesion molecules VCAM-1, ICAM-1 and LFA, is induced in the presence of TNF-α and the adhesion of MM cells to BMSC. In vitro proliferation of MM cell lines and inhibition of Fas-mediated apoptosis is promoted by IL-6.^[24] Thalidomide and its analogs directly decrease the up-regulation of IL-6 and indirectly through TNF-α, thereby reducing the secretion of adhesion molecules leading to fewer MM cells adhering to BMSC. Osteoclasts become highly active during MM, leading to bone resorption and secretion of various MM survival factors. They decrease the levels of adhesion molecules paramount to osteoclast activation, decrease the formation of the cells that form osteoclasts and down-regulate cathepsin K, an important cysteine protease expressed in osteoclasts.^[27]

Apremilast

In vitro, apremilast reduces PDE4 activity leading to an increase in cyclic-adenosine monophosphate (cAMP) concentrations in immune and non-immune cell types, partially inhibiting the production of many pro-inflammatory cytokines such as TNF-α, IFN-γ IL-2, IL-12 and IL-23 and elevating the production of the anti-inflammatory cytokine IL-10. ^[29][30] The inhibition potency of apremilast in TNF-α production is similar to lenalidomide.^[31]

Teratogenicity

Thalidomide‘s teratogenicity has been a subject of much debate and over the years numerous hypotheses have been proposed. Two of the best-known have been the anti-angiogenesis hypothesis and oxidative stress model hypothesis, with considerable experimental evidence supporting these two hypotheses regarding thalidomide's teratogenicity.^[32]

Recently, new findings have emerged that suggest a novel mechanism of teratogenicity. Cereblon is a 51 kDa protein localized in the cytoplasm, nucleus and peripheral membrane of cells in numerous parts of the body.^[22] It acts as a component of the E3 ubiquitin ligase, regulating various developmental processes, including embryogenesis, carcinogenesis and cell cycle regulation, through degradation (ubiquitination) of unknown substrates. Thalidomide has been shown to bind to cereblon, inhibiting the activity of the E3 ubiquitin ligase, resulting in accumulation of the ligase substrates and downregulation of fibroblast growth factor 8 (FGF8) and FGF10. This disrupts the positive feedback loop between the two growth factors, possibly causing both multiple birth defects and anti-myeloma effects. Findings also support the hypothesis that an increase in the expression of cereblon is an essential element of the anti-myeloma effect of both lenalidomide and pomalidomide.^[32] Cereblon expression was three times higher in responding patients compared to non-responders and higher cereblon expression was also associated with partial or full response while lower expression was associated with stable or progressive disease.^[22]

Clinical and possible use

Thalidomide

Thalidomide has been approved by the FDA for ENL and MM in combination with dexamethasone. EMA has also approved it to treat MM in combination with prednisone and/or melphalan. Orphan indications by the FDA include graft versus host disease, mycobacterial infection, recurrent aphthous ulcers, severe recurrent aphthous stomatitis, primary brain malignancies, HIV-associated wasting syndrome, Crohn's disease, Kaposi’s sarcoma, myelodysplastic syndrome and hematopoietic stem cell transplantantion.^[15][33]

Lenalidomide

Lenalidomide is approved in nearly 70 countries, in combination with dexamethasone for the treatment of patients with MM who have received at least one prior therapy. Orphan indications include diffuse large B-cell lymphoma, chronic lymphocytic leukemia and mantle cell lymphoma. Lenalidomide is also approved for transfusion-dependent anemia due to low or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities in the US, Canada, Switzerland, Australia, New Zealand, Malaysia, Israel and several Latin American countries, while marketing authorization application is currently being evaluated in a number of other countries.^[34][35] Numerous clinical trials are already in the pipeline or being conducted to explore further use for lenalidomide, alone or in combination with other drugs. Some of these indications include acute myeloid leukemia, follicular lymphoma, MALT lymphoma, Waldenström macroglobulinemia, lupus erythematosus, Hodgkin's lymphoma, myelodysplastic syndrome and more.^[36][37]

Pomalidomide

Pomalidomide was submitted for FDA approval on 26 April 2012^[38] and on 21 June it was announced that the drug would get standard FDA review. A marketing authorization application was filed to EMA 21 June 2012, where a decision could come as soon as early 2013. EMA has already granted pomalidomide an orphan designation for primary myelofibrosis, MM, systemic sclerosis, post-polycythaemia and post-essential thrombocythaemia myelofibrosis.^[39]

Apremilast

As of September 2012 apremilast is in phase III trials for psoriasis and phase II trials for rheumatoid arthritis. Efficacy in ankylosing spondylitis is also being tested.^[29] As of March 2014 apremilast has been approved for psoriatic arthritis.^[40] In September 2014, the US FDA approved apremilast for the treatment of moderate to severe plaque psoriasis.

Development

The thalidomide molecule is a synthetic derivative of glutamic acid and consists of a glutarimide ring and a phthaloyl ring^[21][41] Its IUPAC name is (2-(2,6-dioxo-3-piperidyl)isoindoline-1,3dione) and it has one chiral center^[21] After thalidomide‘s selective inhibition of TNF-α had been reported a renewed effort was put in thalidomide's clinical development. The clinical development led to the discovery of new analogs which strived to have improved activities and decreased side-effects.^[7][42] Clinically thalidomide has always been used as a racemate. Generally the S-isomer is associated with the infamous teratogenic effects of thalidomide and the R- isomer is devoid of the teratogenic properties but conveys the sedative effects,^[7] however this view is highly debated and it has been argued that the animal model that these different R- and S- effects were seen in was not sensitive to the thalidomide teratogenic effects. Later reports in rabbits, which is a sensitive species, unveiled teratogenic effects from both isomers.^{[7][21][41][42]} Moreover the thalidomide enantiomers have been shown to be interconversed in vivo, due to the acidic chiral hydrogen in the asymmetric center (shown, for the EM-12 analog, in figure 3),^[41][42] so the plan to administer a purified single enantiomer to avoid the teratogenic effects will most likely be in vain.^[7][21][41]

Development of lenalidomide and pomalidomide

Figure 3: Molecular structure of EM-12, an analog of thalidomide. The acidic chiral hydrogen is highlighted

One of the analogs of interest was made by isoindolinone replacement of the phthaloyl ring. It was given the name EM-12 (Figure 3). This replacement was thought to increase the bioavailability of the substance because of increased stability. The molecule had been reported to be an even more potent teratogenic agent than thalidomide in rats, rabbits and monkeys. Additionally, these analogs are more potent inhibitors of angiogenesis than thalidomide.^[12] As well, the amino-thalidomide and amino EM-12 were potent inhibitors of TNF-α.^[41] These two analogs later got the name lenalidomide, which is the EM-12 amino analog, and pomalidomide, the thalidomide amino analog.^[7]

Development of apremilast

Figure 4: Molecular structure of Apremilast, an analog of thalidomide

After finding a novel set of analogs of thalidomide, namely 3-(1,3-dioxo-1,3 dihydroisoindol-2-yl)-3-(3,4-dimethoxyphenyl) propionic acid (Not shown), which had PDE4 inhibition activity the work began to optimize the activity. For that purpose the researchers used a known structure moiety, 3,4-dialkoxyphenyl, that is a recognized pharmacophore in PDE4 inhibitors such as rolipram (figure 5) and roflumilast and added it onto the structure of the previously mentioned analog series. After tweaking the structure and testing different substitution at the 4-position of the phthaloyl ring and at the carboxyl acid the researchers finally landed at a molecule that potently inhibits PDE4 and TNF-α, which they later named apremilast. The S-enantiomer of apremilast was chosen since it was the more active enantiomer.^[21] Since the structure of apremilast lacks the acidic chiral hydrogen it should not racemize in vivo, unlike thalidomide, lenalidomide and pomalidomide.^[41][42]

Structure activity relationship

Figure 5: Thalidomide with the ring system outlined

Since the mechanism of action of thalidomide and its analogs is not fully clear and the bioreceptor for these substances has not been identified, the insight into the relationship between the structure and activity of thalidomide and its analogs are mostly derived from molecular modelling and continued research investigation.^[42][43] The information on SAR of thalidomide and it‘s analogs is still in process so any trends detailed here are observed during individual studies. Research has mainly focused on improving the TNF-α and PDE4 inhibition of thalidomide,^[7][21] as well as the anti-angiogenesis activity.^[44][45]

TNF-α inhibitors (not via PDE4)

Research indicated that a substitution at the phthaloyl ring would increase TNF-α inhibition activity (Figure 5). An amino group substitution was tested at various locations on the phthaloyl ring (C4, C5, C6, C7) of thalidomide and EM-12 (previously described). Amino addition at the C4 location on both thalidomide and EM-12 resulted in much more potent inhibition of TNF-α. This also revealed that the amino group needed to be directly opposite the carbonyl group on the isoindolinone ring system for the most potent activity.^[46] These analogs do not inhibit PDE4 and therefore do not act by PDE4 inhibition. Other additions of longer and bigger groups at the C4 and C5 position of the phthaloyl ring system of thalidomide, some with an olefin functionality, have been tested with various results. Increased inhibitory effect, compared to thalidomide, was noticed with the groups that had an oxygen atom attached directly to the C5 or C4 olefin. Iodine and bromide addition at C4 or C5 resulted in equal or decreased activity compared to thalidomide.^[47] These groups were not compared with lenalidomide or pomalidomide.

PDE4 inhibitors

Figure 6: Rolipram, highlighting the 3,4 dialkoxyphenyl moiety

Figure 7: Common structure for PDE4 inhibition SAR of thalidomide analogs

The common structure for analogs that inhibit TNF-α via inhibition of PDE4 is prepared on the basis of hydrolysing the glutarimide ring of thalidomide. These analogs do not have an acidic chiral hydrogen, unlike thalidomide, and would therefore be expected to be chirally stable.^[41]

On the phenyl ring, a 3,4 dialkoxyphenyl moiety (Figure 6) is a known pharmacophore in PDE4 inhibitors such as rolipram. Optimal activity is achieved with a methoxy group at the 4-position (X2) and a bigger group, such as cyclopentoxy at the 3-position carbon (X3). However the thalidomide PDE4 inhibitory analogs do not follow the SAR of rolipram analogs directly. For thalidomide analogs, an ethoxy group at X3 and a methoxy group at X2, with X1 being just a hydrogen, gave the highest PDE4 and TNF-α inhibition.^[21] Substitutes larger than diethoxy at the X2-X3 position had decreased activity. The effects of these substitutions seem to be mediated by steric effects.^[41]

For the Y-position, a number of groups have been explored. Substituted amides that were larger than methylamide (CONHCH₃) decrease PDE4 inhibition activity.^[41] Using a carboxylic acid as a starting point, an amide group has similar PDE4 inhibition activity but both groups were shown to be a considerably less potent than a methyl ester group, which had about sixfold increase in PDE4 inhibitory activity. Sulfone group had similar PDE4 inhibition as the methyl ester group. The best PDE4 inhibition was observed when a nitrile group was attached, which has 32 times more PDE4 inhibitory activity than the carboxyl acid.^[21] Substituents at Y leading to increasing PDE4 inhibitory activity thus followed the order:

COOH ≤ CONH₂ ≤ COOCH₃ ≤ SO₂CH₃ < CN

Substitutions on the phthaloyl ring have been explored and it was noticed that nitro groups at the 4C or 5C location decreased activity but 4C or 5C amino substitution increased it dramatically.^[41] When the substitution at the 4 (Z) location on the phthaloyl ring was examined, hydroxyl and methoxy groups seem to make the analog a less potent PDE4 inhibitor. An increase in activity was observed with amino and dimethylamino to a similar extent but a methyl group improved the activity further than the aforementioned groups. A 4-N-acetylamino group had slightly lower PDE4 inhibitory activity, compared with the methyl group, but increased the compounds TNF-α inhibitory activity to a further extent.^[21] Substituents at Z leading to increasing PDE4 inhibitory activity thus followed the order:

N(CH₃)₂ ≤ NH₂ < NHC(O)CH₃ < CH₃

Angiogenesis inhibition

Figure 8: Common structure for thalidomide analogs with angiogenesis inhibition

For angiogenesis inhibition activity, an intact glutarimide ring seems to be required. Different groups were tested in the R position. The substances that had nitrogen salts as the R group showed good activity. The improved angiogenesis inhibitory activity could be due to increased solubility or that the positively charged nitrogen has added interaction with the active site. Tetrafluorination of the phthaloyl ring seems to increase the angiogenesis inhibition.^[44]

Synthesis

Described here are ways of synthesising thalidomide, lenalidomide, pomalidomide and apremilast.

Thalidomide

Scheme 1: Thalidomide synthesis, the older procedure

Scheme 2: Newer thalidomide synthesis, two step reaction

Synthesis of thalidomide has usually been performed as seen in scheme 1. This synthesis is a reasonably simplistic three step process. The downside of this process however is that the last step requires a high-temperature melt reaction which demands multiple recrystallizations and is not compliant with standard equipment.
Scheme 2 is the newer synthesis route which was designed to make the reaction more direct and to produce better yields. This route uses L-glutamine rather than L-glutamic acid as a starting material and by letting it react with N-carbethoxyphthalimide gives N-phthaloyl-L-glutamine (4), with 50-70% yield. The substance 4 is then stirred in a mixture with carbonyldiimidazole (CDI) with enough 4-dimethylaminopyridine (DMAP) in tetrahydrofuran (THF) to catalyze the reaction and heated to reflux for 15–18 hours. During the reflux thalidomide crystallizes out of the mixture. The final step gives 85-93% yield of thalidomide, bringing the total yield to 43-63%.^[48]

Lenalidomide and pomalidomide

Scheme 3: Pomalidomide synthesis

Both of the amino analogs are prepared from the condensation of 3-aminopiperidine-2,6-dione hydrochloride (Compound 3) which is synthesized in a two step reaction from commercially available Cbz-L-glutamine. The Cbz-L-glutamine is treated with CDI in refluxing THF to yield Cbz-aminoglutarimide. To remove the Cbz protecting group hydrogenolysis, under 50-60 psi of hydrogen with 10% Pd/C mixed with ethyl acetate and HCl, was performed. The formulated hydrochloride (Compound 3 in Scheme 3) was then reacted with 3-nitrophthalic anhydride in refluxing acetic acid to yield the 4-nitro substituted thalidomide analog and the nitro group then reduced with hydrogenation to give pomalidomide.^[46]

Scheme 4: Lenalidomide synthesis

Lenalidomide is synthesized in a similar way using compound 3 (3-aminopiperidine-2,6-dione) treated with a nitro-substituted methyl 2-(bromomethyl) benzoate, and hydrogenation of the nitro group.^[46]

Apremilast

Scheme 5: Synthesis of apremilast

In the synthesis of apremilast, compound 3 in scheme 5 is produced in a 41% yield from compound 2 treated with lithium hexamethyldisilazide, in mixture with lithium dimethylsulfone and boron trifluoride etherate. The resolution of compound 3 was accomplished by treating it with N-acetyl-L-leucine yielding 3S. The final step then uses condensation of 3-N-acetylaminophthalic anhydride with 3S to afford apremilast (1S) in 75% yield.^[21]

See also

• Cancer
• Multiple myeloma
• Drug design
• Thalidomide
• Lenalidomide
• Pomalidomide
• Apremilast
• Organic chemistry
• Health crisis
• Immunomodulation therapy
• Immunosuppressant
• Immunomodulatory drug

References

1. Aragon-Ching AB, Li H, Gardner ER, Figg WD (2007). "Thalidomide analogues as anticancer drugs". Recent Pat Anticancer Drug Discov. 2 (2): 167–174. doi:10.2174/157489207780832478. PMC 2048745. PMID 17975653.
2. Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the "War" Against Cancer - Onco'Zine - The International Oncology Network (November 30, 2013)
3. Mazzoccoli, L; Cadoso, SH; Amarante, GW; de Souza, MV; Domingues, R; Machado, MA; de Almeida, MV; Teixeira, HC (July 2012). "Novel thalidomide analogues from diamines inhibit pro-inflammatory cytokine production and CD80 expression while enhancing IL-10.". Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 66 (5): 323–9. doi:10.1016/j.biopha.2012.05.001. PMID 22770990.
4. Prommer, E. E. (20 October 2009). "Review Article: Palliative Oncology: Thalidomide". American Journal of Hospice and Palliative Medicine 27 (3): 198–204. doi:10.1177/1049909109348981.
5. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (April 1994). "Thalidomide is an inhibitor of angiogenesis". Proc. Natl. Acad. Sci. U.S.A. 91: 4082–5. doi:10.1073/pnas.91.9.4082. PMC 43727. PMID 7513432.
6. Verheul HM, Panigrahy D, Yuan J, D'Amato RJ (January 1999). "Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits". Br. J. Cancer 79: 114–8. doi:10.1038/sj.bjc.6690020. PMC 2362163. PMID 10408702.
7. Bartlett, J. Blake; Dredge, Keith; Dalgleish, Angus G. (1 April 2004). "Timeline: The evolution of thalidomide and its IMiD derivatives as anticancer agents". Nature Reviews Cancer 4 (4): 314–322. doi:10.1038/nrc1323. PMID 15057291.
8. D'Amato RJ, Lentzsch S, Anderson KC, Rogers MS (December 2001). "Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma". Semin. Oncol. 28: 597–601. doi:10.1016/S0093-7754(01)90031-4. PMID 11740816.
9. Zimmerman, Todd (1 May 2009). "Immunomodulatory agents in oncology". Update on Cancer Therapeutics 3 (4): 170–181. doi:10.1016/j.uct.2009.03.003.
10. Zeldis, Jerome B.; Knight, Robert; Hussein, Mohamad; Chopra, Rajesh; Muller, George (1 March 2011). "A review of the history, properties, and use of the immunomodulatory compound lenalidomide". Annals of the New York Academy of Sciences 1222 (1): 76–82. doi:10.1111/j.1749-6632.2011.05974.x.
11. http://vectorblog.org/2013/04/from-thalidomide-to-pomalyst-better-living-through-chemistry/
12. D'Amato, RJ; Lentzsch, S; Anderson, KC; Rogers, MS (December 2001). "Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.". Seminars in oncology 28 (6): 597–601. doi:10.1016/S0093-7754(01)90031-4. PMID 11740816.
13. Lentzsch S, Rogers MS, LeBlanc R; et al. (April 2002). "S-3-Amino-phthalimido-glutarimide inhibits angiog... [Cancer Res. 2002] - PubMed - NCBI". Cancer Res. (ncbi.nlm.nih.gov) 62: 2300–5. PMID 11956087.
14. Chung, F. (1 September 2004). "Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients". Clinical Cancer Research 10 (17): 5949–5956. doi:10.1158/1078-0432.CCR-04-0421.
15. "Summary of product characteristics: Thalidomid Celgene" (PDF). European Medicines Agency. Retrieved 23 September 2012.
16. Armoiry, X.; Aulagner, G.; Facon, T. (1 June 2008). "Lenalidomide in the treatment of multiple myeloma: a review". Journal of Clinical Pharmacy and Therapeutics 33 (3): 219–226. doi:10.1111/j.1365-2710.2008.00920.x. PMID 18452408.
17. Richardson, P. G. (12 July 2002). "Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma". Blood 100 (9): 3063–3067. doi:10.1182/blood-2002-03-0996.
18. Schey, S.A. (15 August 2004). "Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma". Journal of Clinical Oncology 22 (16): 3269–3276. doi:10.1200/JCO.2004.10.052.
19. Hoffmann, Matthew; Kumar, Gondi; Schafer, Peter; Cedzik, Dorota; Capone, Lori; Fong, Kei-Lai; Gu, Zheming; Heller, Dennis; Feng, Hao; Surapaneni, Sekhar; Laskin, Oscar; Wu, Anfan (1 December 2011). "Disposition, metabolism and mass balance of [ C]apremilast following oral administration". Xenobiotica 41 (12): 1063–1075. doi:10.3109/00498254.2011.604745.
20. Gottlieb, AB; Strober, B; Krueger, JG; Rohane, P; Zeldis, JB; Hu, CC; Kipnis, C (May 2008). "An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.". Current medical research and opinion 24 (5): 1529–38. doi:10.1185/030079908X301866. PMID 18419879.
21. Man, Hon-Wah; Schafer, Peter; Wong, Lu Min; Patterson, Rebecca T.; Corral, Laura G.; Raymon, Heather; Blease, Kate; Leisten, Jim; Shirley, Michael A.; Tang, Yang; Babusis, Darius M.; Chen, Roger; Stirling, Dave; Muller, George W. (26 March 2009). "Discovery of ( )-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor". Journal of Medicinal Chemistry 52 (6): 1522–1524. doi:10.1021/jm900210d. PMID 19256507.
22. Martiniani, Roberta; Di Loreto, Valentina; Di Sano, Chiara; Lombardo, Alessandra; Liberati, Anna Marina (1 January 2012). "Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma". Advances in Hematology 2012: 1–11. doi:10.1155/2012/842945.
23. Huang, Yen-Ta; Hsu, Chih W.; Chiu, Ted H. (1 September 2008). "Thalidomide and Its Analogs as Anticancer Agents". Tzu Chi Medical Journal 20 (3): 188–195. doi:10.1016/S1016-3190(08)60034-8.
24. Melchert, Magda; List, Alan (1 July 2007). "The thalidomide saga". The International Journal of Biochemistry & Cell Biology 39 (7-8): 1489–1499. doi:10.1016/j.biocel.2007.01.022.
25. Quach, H; Ritchie, D; Stewart, A K; Neeson, P; Harrison, S; Smyth, M J; Prince, H M (12 November 2009). "Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma". Leukemia 24 (1): 22–32. doi:10.1038/leu.2009.236. PMC 3922408. PMID 19907437.
26. Thomas, Sheeba K.; Richards, Tiffany A.; Weber, Donna M. (1 December 2007). "Lenalidomide in multiple myeloma". Best Practice & Research Clinical Haematology 20 (4): 717–735. doi:10.1016/j.beha.2007.09.002.
27. Kotla, Venumadhav; Goel, Swati; Nischal, Sangeeta; Heuck, Christoph; Vivek, Kumar; Das, Bhaskar; Verma, Amit (1 January 2009). "Mechanism of action of lenalidomide in hematological malignancies". Journal of Hematology & Oncology 2 (1): 36. doi:10.1186/1756-8722-2-36. PMID 19674465.
28. Vacca A, Ribatti D, Roncali L, et al. (July 1994). "Bone marrow angiogenesis and progression in multiple myeloma". Br. J. Haematol. 87 (3): 503–8. doi:10.1111/j.1365-2141.1994.tb08304.x. PMID 7527645.
29. Schafer, Peter (1 June 2012). "Apremilast mechanism of action and application to psoriasis and psoriatic arthritis". Biochemical Pharmacology 83 (12): 1583–1590. doi:10.1016/j.bcp.2012.01.001.
30. Schafer, PH; Parton, A; Gandhi, AK; Capone, L; Adams, M; Wu, L; Bartlett, JB; Loveland, MA; Gilhar, A; Cheung, Y-F; Baillie, GS; Houslay, MD; Man, H-W; Muller, GW; Stirling, DI (1 February 2010). "Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis". British Journal of Pharmacology 159 (4): 842–855. doi:10.1111/j.1476-5381.2009.00559.x.
31. Michelli, Miranda L. Liver cirrhosis : causes, diagnosis, and treatment (PDF). New York: Nova Biomedical Books. ISBN 978-1-61209-248-5.
32. Ito, Takumi; Handa, Hiroshi (1 March 2012). "Deciphering the mystery of thalidomide teratogenicity". Congenital Anomalies 52 (1): 1–7. doi:10.1111/j.1741-4520.2011.00351.x.
33. "Thalidomide Celgene (previously Thalidomide Pharmion)". European Medicines Agency. Retrieved 18 September 2012.
34. "Celgene Biopharmaceutical - Investor relations - Press Releases". Retrieved 18 September 2012.
35. "Revlimid (lenalidomide) dosing, indications, interactions, adverse effects, and more". Medscape references. Retrieved 18 September 2012.
36. "Search of: lenalidomide - List Results". Clinical Trials. Retrieved 18 September 2012.
37. "Clinical Trials Register". EU Clinical Trials Register. Retrieved 18 September 2012.
38. "Celgene Submits Pomalidomide For FDA Approval". The myeloma beacon.
39. "European Medicines Agency - Search results from your query". European Medicines Agency. Retrieved 18 September 2012.
40. "FDA approves Otezla to treat psoriatic arthritis". fda.gov. Retrieved 13 June 2014.
41. Muller, George W.; Corral, Laura G.; Shire, Mary G.; Wang, Hua; Moreira, Andre; Kaplan, Gilla; Stirling, David I. (1 January 1996). "Structural Modifications of Thalidomide Produce Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity". Journal of Medicinal Chemistry 39 (17): 3238–3240. doi:10.1021/jm9603328. PMID 8765505.
42. Man, Hon-Wah; Corral, Laura G; Stirling, David I; Muller, George W (1 October 2003). "α-Fluoro-substituted thalidomide analogues". Bioorganic & Medicinal Chemistry Letters 13 (20): 3415–3417. doi:10.1016/S0960-894X(03)00778-9. PMID 14505639.
43. Avila, Carolina Martins; Romeiro, Nelilma Correia; Sperandio da Silva, Gilberto M.; Sant’Anna, Carlos M.R.; Barreiro, Eliezer J.; Fraga, Carlos A.M. (1 October 2006). "Development of new CoMFA and CoMSIA 3D-QSAR models for anti-inflammatory phthalimide-containing TNFα modulators". Bioorganic & Medicinal Chemistry 14 (20): 6874–6885. doi:10.1016/j.bmc.2006.06.042.
44. Lepper, Erin R.; Ng, Sylvia S. W.; Gütschow, Michael; Weiss, Michael; Hauschildt, Sunna; Hecker, Thomas K.; Luzzio, Frederick A.; Eger, Kurt; Figg, William D. (1 April 2004). "Comparative Molecular Field Analysis and Comparative Molecular Similarity Indices Analysis of Thalidomide Analogues as Angiogenesis Inhibitors". Journal of Medicinal Chemistry 47 (9): 2219–2227. doi:10.1021/jm0304820.
45. Noguchi, Tomomi; Fujimoto, Haruka; Sano, Hiroko; Miyajima, Atsushi; Miyachi, Hiroyuki; Hashimoto, Yuichi (1 December 2005). "Angiogenesis inhibitors derived from thalidomide". Bioorganic & Medicinal Chemistry Letters 15 (24): 5509–5513. doi:10.1016/j.bmcl.2005.08.086.
46. Muller, GW; Chen, R; Huang, SY; Corral, LG; Wong, LM; Patterson, RT; Chen, Y; Kaplan, G; Stirling, DI (Jun 7, 1999). "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.". Bioorganic & Medicinal Chemistry Letters 9 (11): 1625–30. doi:10.1016/s0960-894x(99)00250-4. PMID 10386948. Retrieved 24 September 2012.
47. Stewart, Scott G.; Spagnolo, Daniel; Polomska, Marta E.; Sin, Melvin; Karimi, Mahdad; Abraham, Lawrence J. (1 November 2007). "Synthesis and TNF expression inhibitory properties of new thalidomide analogues derived via Heck cross coupling". Bioorganic & Medicinal Chemistry Letters 17 (21): 5819–5824. doi:10.1016/j.bmcl.2007.08.042.
48. Muller, George W.; Konnecke, William E.; Smith, Alison M.; Khetani, Vikram D. (1 March 1999). "A Concise Two-Step Synthesis of Thalidomide". Organic Process Research & Development 3 (2): 139–140. doi:10.1021/op980201b.